Inhal Pharma is committed to cutting-edge R&D, production, and commercialization of technologies on DPI formulation, filling equipment, and inhaler for new drug and generic drug. We are looking for opportunities cooperating with innovative API suppliers, leading pharmaceutical sensor developers, and higher education institutes that have top of the class drug development capabilities.
Established in 2004, Ningbo Menovo Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise which integrates R&D, pilot plant test, production, and sales of pharmaceutical intermediates, APIs and finished medicines.
Real Harmony is an angel investor of Inhal. In 2020, it invested in Inhal with Ningbo Angel Investment Guidance Fund to support Inhal’s research, development and production of inhalation products and devices.
With an agreement assigned on 28 September 2020, Particle Technology Centre of Western University and Ningbo Inhal are engaged in a strategic cooperative scheme fostered from mutual interest, benefits and commitment to dry power inhalation preparation.
Since Ningbo Inhal was established, the University of Nottingham Ningbo has introduced innovative talents from different fields to Inhal. Talent sources include the Nottingham Business School, Dept of Chemical Engineering, and Dept of Industrial Design.
Zhejiang University of Technology (ZJUT) and Inhal have been jointly building a platform for pharmacodynamics evaluation of inhaled preparations since 2020.
China Pharmaceutical University and Inhal started to build a joint laboratory for precise delivery technology for micro-nano granules in 2021. The two parties will cooperate in production, education, and research in the field of dry powder inhalation.